Project Alert

Aldevron is building its second GMP manufacturing facility, the latest one to be 189,000 sq. ft. residing on the company's existing 14 acre site in Fargo, North Dakota. The new manufacturing facility is expected to be fully operational by Q1 of 2021. In total, three new buildings are slated to be built over the next three to five years to support the rapidly growing field of genetic medicine. Learn More

RoslinCT has begun construction of the expansion of their new manufacturing center. The new state of the art 17,000 sq. ft. (1,600 m2) facility will operate to US and EU GMP standards and will become an innovative hub for the manufacture of cell and gene therapy products. The new custom-designed facility will encompass five clean rooms, warehousing and offices for all supporting activities and will include a dedicated training lab. Learn More

The Altec Styslinger Genomic Medicine and Data Sciences Facility would encompass 145,000 sq. ft. of lab and office space at the Birmingham campus of the University of Alabama. Earlier this month, the UA System Board passed a Stage III approval, which will allow the design and bidding of the project to proceed-although final Stage IV approval is still required at a future meeting. Current plans would include the renovation and expansion of the Lyons Harrison Research Building at 701 19th Street South. The development would also involve demolishing the adjacent Pittman Center for Advanced Medical Studies Building and the Kracke Building. Learn More

Plans are moving forward for Selkirk Pharma's $30 million manufacturing facility on the West Plains. The company, a CMO, intends to build a 65,000-square-foot manufacturing facility at 9110 W. Granite Ave. in the Pacific Northwest Technology Park, according to an application filed with the city of Spokane. This same application notes that construction is expected to begin in August of this year and is slated for completion in December 2021. Learn More

Plans are moving forward for Selkirk Pharma's $30 million manufacturing facility on the West Plains. The company, a CMO, intends to build a 65,000-square-foot manufacturing facility at 9110 W. Granite Ave. in the Pacific Northwest Technology Park, according to an application filed with the city of Spokane. This same application notes that construction is expected to begin in August of this year and is slated for completion in December 2021. Learn More

Cellular Technology Limited (CTL), a global biotech company has closed on the purchase of the 36,700 sq. ft. Chagrin Corporate Center in Shaker Heights, Ohio. To support the planned expansion the city has proposed amendments to its zoning code to allow not only for expanded uses in office space, but also more flexibility in adding laboratories and research facilities, along with "limited production processing," to what has been a very short list of permitted uses in the city's Office Districts. Learn More

Oxford Biomedica has signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC). This five-year Agreement will involve the organizations working collaboratively to enable the manufacture of viral vector based vaccines, contributing towards a rapid increase in UK domestic capacity for this specialized field of vaccine manufacturing. As part of the Collaboration Agreement, VMIC will provide manufacturing equipment for Oxford Biomedica to rapidly equip two new GMP manufacturing suites within Oxford Biomedica's new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, UK. Learn More

Fujifilm has made public plans to invest roughly $928 million in the Denmark site of FUJIFILM Diosynth Biotechnologies. The investment will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023, making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry. The development will also include the addition of the Denmark site's first fill/finish production line (added by summer 2023), featuring a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production. Learn More

WuXi Biologics has announced that it has signed a 10-year lease for a clinical manufacturing facility (MFG18) in Cranbury, New Jersey. The new clinical manufacturing facility will feature a total of 6000 L of bioreactor capacity as well as Process Development (PD) suites, Quality Control (QC) labs, all of which accompanied by supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region. This is the third plant for WuXi Biologics in the U.S. joining a previously announced manufacturing site in Worcester, Massachusetts and a PD lab in King of Prussia, Pennsylvania. Learn More

Plans for a new 10-story, 500,000 square-foot bioscience lab and office tower to be built atop the former Route 34 corridor have advanced in New Haven, Connecticut. The tower, to be built at 1010 College Street, is expected to cost upwards of $100 million. Local firm Winstanley Construction is heading up the re-development of the site including construction. Learn More

Biotech firm GRAIL, headquartered in Menlo Park, California, has promised to invest at least $103 million to build a 200,000-square-foot "state-of-the art" laboratory in Durham. It will include an office and warehouse space in North Carolina's Research Triangle Park. GRAIL is a healthcare company whose mission is to detect cancer early. It is using the power of next-generation sequencing, population-scale clinical studies, and computer and data science to enhance the scientific understanding of cancer biology and develop a multi-cancer early detection blood test. Since early 2016, GRAIL has raised more than $1.9 billion in four rounds of equity financing. Learn More

AGC Biologics has announced that it has acquired AstraZeneca's 300,000-square-foot facility in Boulder and will revive manufacturing operations there in April. The Japanese biopharma, which provides contract development and manufacturing services globally, said it will invest $100 million in and employ 280 workers at the facility, located at 5550 Airport Blvd. The Boulder plant houses two 20,000-liter stainless steel mammalian cell bioreactors, and the company noted it could fit up to four more on its 20 acres. Alert readers will recall that AstraZeneca acquired the facility from Amgen in 2015 which had shut it down in 2012. Learn More

POINT Biopharma, a global, clinical-stage pharmaceutical company specializing in the development and production of radiopharmaceuticals for cancer treatments, will establish its first U.S. manufacturing facility in Indianapolis, Indiana. POINT will invest more than $25 million to purchase and transform an existing 77,000-square-foot, food-grade building at 4850 W. 78th St. in Indianapolis into a state-of-the-art, Good Manufacturing Practices facility. The company expects to move into its new space this year and to be fully operational by 2021. Learn More

Takara Bio has bought two buildings totaling 129,000 sq. ft. from the University of California Regents. The company will shift its local headquarters from Mountain View, where it currently is a tenant, to the pair of north San Jose buildings. Takara paid $44.8 million for the two buildings, according to property documents filed with county officials on May 12th. The two properties, located at 2560 and 2570 Orchard Parkway are part of the four-building Valley Research Center, near the corner of Orchard Parkway and West Trimble Road and just down the block from North First Street and its light rail lines. The deal appears to position Takara for a significant expansion. Learn More

Meissner's new manufacturing facility is roughly 42,000 sq. ft. in size and features a state of the art 10,000 sq. ft. class 7 cleanroom dedicated to the manufacture of single-use systems. Validation of the facility was completed in min-April and the facility is currently manufacturing products for their biopharma clients. Anticipating future expansions at the time of purchase, Meissner included adjacent land with initial groundwork for this development set to begin later this year. Learn More

NewAge Industries has closed a deal to buy two building units at a location within seven miles of its southeastern Pennsylvania headquarters. The two building units consist of 46,000 sq. ft. of manufacturing space with an additional 3,000 sq. ft. of offices. The manufacturing area will house tubing extrusion machinery, injection molding presses, clean rooms for high purity product manufacturing and packaging, and quality inspection areas. Quality department personnel and department supervisors will use the office space. NewAge plans to inventory and ship products directly from the new location. Renovations at the new location will begin this summer with additional remodeling extending into next year. Learn More

Life-science real estate firm IQHQ this week announced that it has acquired Innovation Park in Andover with plans to spruce up its amenities. The developer plans to redesign the 200,000 square foot campus on 4 Corporate Drive, adding new amenities such as a cafe and fitness center, which will both have indoor and outdoor spaces. Citing an increasing demand for office and lab space, the company said Innovation Park's newest tenants - the University of Massachusetts Lowell and drug and device development firm Ora Inc. - have signed long-term leases. This is the company's third project in Greater Boston. Learn More

WuXi Biologics and the Worcester Business Development Corporation (WBDC) have announced the successful signing of a land deal for WuXi Biologics' clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus. The approximately 107,000-square-foot, two-story facility will be operational in 2022 and create 150 new jobs. Craig Blais, the president and CEO of the WBDC, stated, "WuXi Biologics' decision to locate its first US biomanufacturing facility in Worcester at The Reactory confirms the value of Worcester's strong life sciences ecosystem. We expect other biotech manufacturers will soon follow their lead." Learn More

Instruments maker Thermo Fisher plans to spend $180 million to build a 290,000-square-foot site that will double capacity to make viral vectors, the inactivated viruses used to convey gene therapies into human cells. The contract development and manufacturing organization plans to complete work on the facility in Plainville, Massachusetts, in 2022 and add more than 200 jobs. Thermo's investment is the latest in a series of expansions designed to meet growing demand for gene therapies and vaccines, the company said in a statement. Learn More

Allakos has committed to 98,133 square feet of pre-lease space at Alexandria Real Estate Equities' The Alexandria District in San Carlos. The biopharma plans to occupy one of two structures under development that total 526,178 square feet. ChemoCentryx previously took 96,000 square feet at the development, with an August move-in date planned. The buildings are within the planned six-building, 1.6-million-square-foot biotech campus near Stanford, and located equidistant between San Francisco and San Jose at 825 Industrial Rd., San Carlos. The company, which has an existing headquarters in Redwood City, plans to take occupancy in the summer of 2021. Learn More

IQHQ, a life sciences real estate development company, will acquire a key development site in South San Francisco to develop into what it hopes will become another premier life science real estate and R&D complex. The two-acre site, currently known as South City Station at 580 Dubuque Avenue, is located in the heart of South San Francisco, one of the West Coast's fastest growing markets for life sciences. The deal is an off-market transaction and is entitled for a 213,000-square foot development. The purchase price was not disclosed. The location is prime as it is immediately adjacent to the new South San Francisco Caltrain Station, which is expected to open in Spring of 2021 and will connect San Jose to Downtown San Francisco. Learn More

The Lonza Biologics facility at Pease International Tradeport is part of a collaborative effort to manufacture a vaccine against the COVID-19 infection. Work at the Portsmouth facility is expected to ramp up in June as biologics for the vaccine are transferred to the plant, according to the company. Alert readers will recall that Moderna announced last week that it is manufacturing a potential COVID-19 vaccine - called mRNA-1273 - in cooperation with Lonza. The vaccine is not yet approved by the U.S. FDA. Having done phase 1 trials in March, the company on April 27 submitted application to the FDA to begin phase 2 trails, with phase 3 trials beginning as soon as fall 2020. Learn More

The New Jersey Innovation Institute (NJII), has launched BioCentriq as its cell and gene therapy production and manufacturing center. BioCentriq is a process development and clinical manufacturing facility for cell and gene therapies located in Newark, NJ. The Biopharma Division has initiated the qualification and validation process for the BioCentriq facility and its equipment. This GMP facility is located at NJIT's Life Sciences and Engineering center and features two GMP suites. The GMP suites are expected to complete their qualification and validation and be operational this summer. BioCentriq also offers a process development center, currently located at the Rutgers Medical School in Newark, which has been supporting projects since late 2019. Learn More

Fujifilm Diosynth has entered into a deal with the Bill Gates funded COVID-19 Therapeutic Accelerator which will devote some of its manufacturing capacity at its Hillerød, Denmark biologics plant for a treatment yet to be identified. The Denmark facility is equipped with six large-scale bioreactors for the manufacture of cell-culture-derived biologics for clinical and commercial use, the company said. The agreement also stipulates Fujifilm will support assembly, labeling and packaging requirements for the to-be-decided pharma partner. The deal sets aside an unspecified production volume for 2021 with options for the following years, Fujifilm said. Learn More

A new biotech research facility in Alachua, Florida has sold for $12 million. According to published reports the facility is one of four scheduled to be developed for Applied Genetic Technologies Corporation (AGTC) which has ongoing operations in the area. The facility, located in Foundation Park, encompasses roughly 43,000 sq. ft. of space and is anticipated to be a sought-after property for biopharma firms in the area looking to expand. In addition to its proximity to AGTC the site is located just across from Progress Park and UF Innovate's Sid Martin Biotechnology Incubator. Learn More

Biopharma ScieGen is expanding its manufacturing operations on Long Island and adding over 100 jobs. The $15 million expansion will help ScieGen, a subsidiary of Bactolac Pharmaceutical, bolster its production of prescription drugs to meet growing demands. The company plans to convert 65,000 s/f of former warehouse space at its facility at 33 Oser Avenue in Hauppauge into manufacturing space with washrooms, an office, labs and a cafeteria. The company says it will use Long Island-based vendors to make the space FDA compliant. Learn More

Catalent has completed a $14 million expansion to increase its biologics packaging capabilities and capacity at its Bloomington, IN facility. The expansion adds 15,000 square feet of packaging infrastructure to the biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory. Catalent has partnered with industry leaders to bring new technologies and integrated capabilities to its three new packaging lines, including an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP® x (NTX) top-load cartoner with both semi-automated and fully-automated configurations. Learn More

MilliporeSigma this week announced an investment of $110 million to construct a second commercial facility in Carlsbad, California. The manufacturing facility, to encompass 140,000 sq. ft., will expand the company's BioReliance® viral and gene therapy service offering. Plans for the site include support for viral and gene therapy production at the 1000-liter scale using MilliporeSigma's Mobius® single-use equipment and the addition of 11 suites capable of supporting various steps in the manufacturing process. These are expected to include viral bulk manufacturing cleanroom suites and fill/finish suites. Learn More

PharmaBlock Sciences has launched a new Chemistry and Engineering Technology Center (CETC) located next to its GMP manufacturing site in Shangyu, Zhejiang Province, China. The new technology center covers an area of 32,300 square feet and cost $8 million. Featuring state of the art assets and experienced chemists and engineers, the CETC is committed to delivering innovative solutions with a focus on flow chemistry, micropacked bed reaction, biocatalysis, and an array of engineering technologies, including but not limited to separation, crystallization, and application of DCS and process simulation. Learn Mor

Australian Biotherapeutics, a joint venture of Servatus, has completed construction of Phase 1 of its new facility in Coolum Beach, Australia. The site, which features capacity for research, development and large scale Manufacturing, was funded in part by the Queensland government. A second stage of the facility build is being planned and is expected to begin soon. Learn More

Cambrex has announced that it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site. Biopharmaceutical analysis services were initially launched at Durham in 2018 and have since been expanded through the purchase and implementation of various method development, validation, release and stability or endotoxin testing functions. Following this expansion, the Durham site now features a range of new instruments, including particle analysis, imaging, qPCR, fluorescent/absorbance plate reader, immunoblotting, mass spectrometry and other compendial testing apparatus. Learn More

Akron Biotech has acquired a state-of-the-art 60,000-square-foot biologics manufacturing site in Sarasota, FL, bolstering the company's U.S. capacity and strengthening its position as an ancillary materials supplier. The site will be operational later this year. The Sarasota site will facilitate rapid growth in each of the company's three main cGMP business verticals: cytokines and growth factors, growth and cryopreservation media, and viral inactivated human-derived media supplements. It also enables the company to add cGMP-compliant plasmid development and production to its custom development and manufacturing services, addressing one of the central bottlenecks in the cell and gene therapy industry. Learn More

Biopharma PTC Therapeutics has signed a seven-year lease for over 100,000 square feet at the New Jersey Center for Excellence campus in Bridgewater. The New Jersey-based company will relocate from its current site in South Plainfield and occupy three floors spanning a total of 101,500 square feet at the 48-acre research and development campus, at 1021 US 202/206. The campus comprises eight buildings, primarily laboratory or research and development facilities, and is anchored by nutritional health company Nestle Health Sciences, chemicals firm Ashland and drug producer Amneal Pharmaceuticals. Learn More

Plans are moving forward for Selkirk Pharma's $30 million manufacturing facility on the West Plains near Spokane, Washington The company, a contract manufacturing biopharma startup, filed an environmental review for the project with the Washington state Department of Ecology last week. The company intends to build a 65,000-square-foot manufacturing facility at 9110 W. Granite Ave. in the Pacific Northwest Technology Park, according to an application filed with the city of Spokane. Construction is expected to begin in August and is slated for completion in December 2021, according to the environmental review. Spokane-based Bernardo|Willis Architects is designing the project. Learn More

A&C has recently expanded its footprint into Europe with the opening of A&C Bio Buffer Ltd, a new state-of-the-art GMP manufacturing facility in Ireland. The Irish facility is ISO 9001:2015 certified and is dedicated to GMP manufacturing of biological buffers, process solutions, cleaning solutions, chemical blends, WFI (water for injection) and GMP raw material repacking. A&C Bio Buffer is the only company in Ireland to manufacture biological buffers with water for injection. The new Irish production site is another significant addition to the A&C Group, which currently has two GMP manufacturing plants in North America. Learn More

A 65,269-square-foot industrial building in the Conejo Valley has sold for $8.1 million, with the new owner looking to turn it into biotech labs. The warehouse, located at 1300 Rancho Conejo Blvd. in Thousand Oaks, sits on 5 acres. The new owner, Alexandria Real Estate Equities, is understood to be planning to redevelop the site to house biotechnology labs to accommodate the rising number of industry users in Ventura County. Alert readers will recall a number of stories in recent months detailing growth in the region particularly among smaller, fast growing biotech companies seeking to replicate the success of local success story Amgen. Learn More

FUJIFILM Diosynth Biotechnologies held a ground breaking ceremony this week signalling commencement of construction of the company's new BioCampus at its Billingham, UK location. This BioCampus development will include the construction of 42,000 square foot purpose-built office accommodation and visitor center in addition to making ready the land for potential expansion that could include additional research and development laboratories and new manufacturing facilities. The construction is expected to be completed by March 2021. Learn More

Bora Pharmaceuticals and GSK have entered into an agreement under which Bora will acquire GSK's Mississauga, Ontario (Canada) facility. The GSK facility produces approximately 50 different products for over 100 markets worldwide and employs approximately 400 skilled manufacturing staff who will be invited to join Bora as part of the transaction. Bora will continue to manufacture, under contract, the existing GSK product line for a minimum of five years. GSK employees in the Pharmaceuticals and Consumer Healthcare commercial businesses, who currently work in office space at the Mississauga site will move to new locations within an agreed timeframe following the close of the transaction. Learn More

Amicus Therapeutics will officially unveil its $25 million global research and gene therapy center in Philadelphia on Thursday of this week. The center, whose laboratory and office space were designed by CRB, was secured by Amicus last year. Alert readers will recall that Amicus entered into a 10-year lease deal for roughly 75,000 square feet spread across the top three floors at 3675 Market Street in University City. The location is ideal for amongst other things its proximity to the company's major gene therapy partner: the University of Pennsylvania with whom Amicus recently expanded its working relationship. Learn More

The cost of the new global headquarters of Britain's biggest drugs company has risen to about $1.3 billion (£1 billion), more than three times the original estimate. Astrazeneca had planned to spend $425 million (£330 million) on the Cambridge site, which will also be its research and development center, but the costs have jumped for a third time to make it one of the most expensive corporate buildings in the country. It is also way behind schedule - it was due to open in 2016. The latest cost estimate comes after a review by Mace, which replaced Skanska as construction manager in 2018. Astrazeneca moved from Alderley Park in Cheshire to the new site on the biomedical campus in the south of Cambridge seven years ago. Learn More

Amunix has made public plans to combine the $73 million generated from its financing round with the $40 million upfront payment received from Roche to advance its lead drug candidate, AMX-818. As part of its plans the company will relocate from Mountain View to South San Francisco, California later this year. Amunix is aiming at developing T-cells to attack and destroy solid tumors without the toxic reactions that have been observed, as well as immunogenicity limitations. No word yet on just where in South San Francisco the company will be located, but the close ties to Roche would suggest the Oyster Point area. Learn More

Exicure has leased 30,000 sq. ft. in a 120,000 sq. ft. building known as The Labs at 2430 N. Halstead in Lincoln Park and plans to move in this Summer. The building is owned by developer Sterling Bay, which is preparing to undertake construction of the $6 billion Lincoln Yards project roughly a mile away. It is expected that biopharma firms will play a prominent role in the 55-acre development as the first phase of construction is expected to include 350,000-400,000 sq. ft. of biopharma research and office space. The total build out of the site has approval to be as much as 14.5 million sq. ft. of mixed use. Learn More

FUJIFILM Cellular Dynamics will begin operations at its new cGMP-compliant iPSC production facility in Madison, WI this week. The new Innovation Facility for Advanced Cell Therapy (i-FACT), will house development and manufacture of iPSCs for therapeutic applications. The i-FACT will enable FCDI to accelerate the development of its own pipeline of regenerative medicine therapies using iPSCs, as well as serve as a CDMO of IPSCs and iPSC-derived differentiated cells. The $21 million, 32,000 sq.-ft. facility features four development labs and three cGMP suites for in-house therapeutic development and for collaboration with other companies. The facility is designed to enable each suite to manufacture a different product to offer scale-up and scale-out biomanufacturing ability to facilitate various batch sizes. Learn More

San Jose BioCube, a long-established life sciences incubator, has announced the availability of 15 move-in-ready wet labs designed for high-potential life sciences startups. Dubbed "BioCube North," the incubator is housed on the ground floor of the Q Bay Center, the 112,232-square-foot facility at 160 East Tasman Drive in San Jose, California. Launching in March, BioCube North's labs will offer over 5,000 square feet of shared space where life-sciences startups have the appropriate plumbing, ventilation, refrigeration and equipment, together with BioCube's global standard of facility management and client care, to grow their businesses. Learn More

FUJIFILM Diosynth Biotechnologies broke ground this week on its North Carolina facility expansion project. The 31,778 square foot addition includes the expansion of its cell culture and microbial manufacturing trains through the addition of new recover and purification suites. The North Carolina site will increase its cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50%. A new receiving warehouse is also included in the project. FDB expects that the increased production capacity will be ready for cGMP manufacture by mid-2021. Learn More

WuXi Vaccines has announced that it has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion. As part of the deal WuXi will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner's vaccine products for the global market. The new facility is expected to be operational in 2022. Learn More

Audentes Therapeutics, a gene therapy developer recently bought by Astellas, will invest about $110 million to build a manufacturing plant in North Carolina, joining a growing list of drugmakers choosing to locate new drug production facilities in the state. For Audentes, the decision to invest in a new facility emerged from planning for when the biotech outgrows the capacity it currently has in a South San Francisco plant, according to Donald Wuchterl, the company's head of technical operations. Audentes cast a wide net for where to place its newest facility, eventually choosing a small town southwest of Raleigh already home to one gene therapy plant, which Pfizer's now spending $500 million to expand. Learn More

Grifols has announced the signing of a non-binding agreement with Saudi Arabia's sovereign wealth fund to help the country produce blood plasma-derived medicines. Barcelona based Grifols and the Saudi Public Investment Fund (PIF) have agreed in principle to create a joint venture that will develop plasma collection centers and production facilities, including a fractionation and a purification facility in Saudi Arabia. Grifols will provide knowledge and intellectual property, and will also supply plasma medicines to Saudi Arabia until the joint venture becomes capable of producing them. No financial details or stakes in the planned joint venture have been made public as of this writing. Learn More

PBSC, the cleanroom components manufacturer based in England, has opened new offices in Massachusetts, United States. The office will be spearheaded by Stephen Grant. Established in 1987, PBSC specializes in manufacturing products for cleanroom, high containment and material decontamination areas. The company boasts an extensive product range, bespoke designs and assembly capabilities. PBSC Inc will be found at Braintree, Massachusetts, the team will work hand-in-hand with its counterpart in the UK. Learn More

WuXi Biologics has awarded Ardmac the roughly 160,000 square feet (15,000 square meters) of specialist cleanroom construction on their purpose-built facility at Mullagharlin in Dundalk, Co. Louth. The CDMO's facility has been described in reports on the project as the "Factory of the Future". Ardmac is expected to employ over 200 people over the course of the project at Dundalk, with completion expected by 2021. The project will be deployed using Ardmac's SMART delivery model, implementing lean principles and techniques coupled with the implementation of the latest digital field collaboration software to support the build efficiently. Learn More

Novo Nordisk has announced plans to invest roughly $115 million (DKK 800 million) in upgrading and expanding the facilities at its production site in Kalundborg, Denmark. The existing facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products. Established in 1969, the site covers a total area of 12.9 million sq. ft. (1.2 million sq. m) and employs more than 3,000 people. Besides diabetes a number of other biopharmaceuticals are produced at the site. The projects are expected to be completed in 2022. Learn More

AstraZeneca has announced that it will invest $200 million into the company's manufacturing facility in North Ryde, Sydney. The investment follows $100 million announced in 2017 and will go towards increasing the facility's production capabilities, creating 250 jobs and increasing exports to $4.4bn over the next four years. The local North Ryde facility is among the most digitized and innovative in the company's global network, delivering medicines to millions of patients who need them in Australia, the Asia-Pacific region and other global markets. Learn More

Exelixis has leased a yet-to-be-built office building at 1951 Harbor Way in Alameda, California that, when constructed and complete, will total 220,000 square feet. The biotech currently occupies a 64,000-square-foot building at 1851 Harbor Bay Parkway. Development of the new headquarters, which could have capacity for as many as 1,100 employees, is expected to begin this summer. However, as of this writing, a precise timeline for completion has not yet been made public. Learn More

Takeda has confirmed it is looking for a buyer for its operations in Dunboyne, Co Meath. The site employs some 200 and Takeda says no redundancies are planned. In a statement, the company said: "As a result of Takeda's acquisition of Shire last year, and subsequent integration, Takeda has decided to divest its biologics facility in Dunboyne." The site was the last major investment made by Shire before it was acquired by Takeda last year. The company invested $415 million (€375 million) in setting up a new biologics manufacturing plant on its 120-acre site in Dunboyne. The company says day-to-day operations at the facility will continue "as we complete commissioning and validation of the facility"... Learn More

Vigene Biosciences has opened its new research facility in Rockville, Maryland. The opening of a new laboratory at 5 Research Court - near Interstate-270's Shady Grove Road exit - significantly increases the biotech's Rockville footprint, adding 51,000 square feet to its existing 20,000 square feet at a separate facility nearby. The project cost more than $20 million, according to Vigene. The company, which partners with therapeutic developers to lower the cost of manufacturing, will now use both facilities for research, development and production. The company first moved into the space, its new global headquarters, in October, after shutting down its former Rockville HQ. Learn More

CDMO Piramal Pharma Solutions has announced plans to expand its Aurora facility in Canada with the addition of a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients (APIs). A total investment of $19 million (CAD$25M) will be invested at the site. The planned expansion will add roughly 10,500 sq. ft. of new manufacturing space to the existing facility and equip it with two new reactor suites as well as a dedicated filter dryer room and a portable filter dryer. The project is expected to be completed and the site operating by April 30th, 2021. Learn More

Krystal Biotech has broken ground on its new biologics manufacturing facility near Pittsburgh, Pennsylvania. The 100,000 sq. ft. building in the Airport Corridor will be primarily used to make the company's gene therapy medicines for rare skin problems. Krystal CEO Krish Krishnan said the building is expected to cost between $70 million and $90 million with a target completion date of 15 months. Staffing for the new building is expected to create 70 initial new jobs with more expected to be added when the site is fully operational. In the meantime, the company will continue to operate from its South Side facilities which include a 4,500 sq. ft. lab. Learn More

Merck KGaA has announced an investment of $275 million (€250 million) in a new facility in Corsier-sur-Vevey, Switzerland - the Merck Biotech Development Center - dedicated to biotech development and manufacturing. Located near Merck's current biotech commercial manufacturing site the Center will bring together research and manufacturing. The facility will consist of a building providing a total of 169,000 sq. ft. (15,700 sqm) of development space. Equipped with continuous manufacturing and laboratory automation, the construction of the Biotech Development Center is expected to be completed in 2021 with the site validated and fully operational by the end of 2022. Learn More

The Center for Breakthrough Medicines, a newly formed CDMO whose mandate is to facilitate patient access to critically needed cell and gene therapies, has signed a long-term lease for 680,000 square feet at The Discovery Labs site in King of Prussia, Pennsylvania. The site, a former GSK campus, will be home to an estimated 2,000 scientists, manufacturing experts, lab technicians and support staff. Plans for the site include 75-100 suites distributed among roughly 26 interconnected buildings. According to published reports, the site is expected to be partially operational by years end and fully operational in 2021. Learn More

GE Healthcare Life Sciences is building a new 79,000 sq. ft. (7,360 sqm) facility in Grens, Switzerland. The site, located in the new Signy Park will be equipped for the manufacture of single-use kits for the Sepax and Sefia cell processing systems. In addition to its manufacturing capabilities, the new site will house a Center of Excellence that will feature advanced cell and gene therapy manufacturing facilities and will also support a growing Research & Development team and other subject matter experts. The facility will meet global regulatory requirements and is expected to be fully operational in 2022. Learn More

AstraZeneca has announced plans for a five-year, $500 million investment in France. The details of the investment includes $230 million to finance the expansion and modernization of the company's development and manufacturing site in Dunkirk. This will include the building of three assembly lines and two packaging lines at the site. With an additional $275 million slated for investment in research and development efforts at company sites across France. Finally, an amount of $15 million has been set aside for the creation of a European Innovation Hub in Paris. Learn More

Eli Lilly and Company has made public plans to build a $470 million dollar biopharma manufacturing plant, creating more than 460 high-paying jobs, in Durham, North Carolina. The decision to build in North Carolina comes after the company conducted a nationwide search for a location for the new plant. Indiana, Pennsylvania and North Carolina were the finalists. According to published reports the new facility will produce injectable products and delivery devices. Alert readers will recall that late last year Lilly announced plans to invest $400 million into its manufacturing facilities at the Lilly Technology Center in Indianapolis. Learn More

Celltrion has made public details of its previously announced 120,000 liter biologics manufacturing facility. The facility, to be built in Wuhan, China, promises to be the country's biggest biologics plant, far exceeding the capacity of the current 5,000 liters facility that serves as China's largest. The site is expected to provide Celltrion with a location from which to both develop and manufacture its own biologics for the Chinese market. According to published reports, plans for the site include the role of CMO for local biotechs. Groundbreaking for the site is planned for this Spring and funding is slated through 2025. 

Leading South Korean biosimilar manufacturer Celltrion has made public plans to build a plant in China in a move to directly advance into the world's second-largest biopharmaceutical market, its chief said. "We are in the final stage of signing a contract with the Chinese government. We will soon announce details of the plant," Chairman Seo Jung-jin said during the annual J.P. Morgan Healthcare Conference. The company's business roadmap centers on building a plant with a production capacity of 120,000 liters in China to boost capacity amid rising demand. According to Celltrion, the planned production facility will be the largest of its kind in China. Learn More

Just - Evotec Biologics has initiated construction of a 130,000 sq. ft. late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington. Construction on the greenfield site, located in Redmond Ridge Business Park, is expected to be completed by late 2020 and operational in the first quarter of 2021. The facility will contain manufacturing pods for implementing intensified fed-batch or continuous processing up to 1,000 L scale, with the capability of manufacturing metric tons of drug substance. Also included are supporting quality labs and process development labs. Learn More

Kite Pharma, a subsidiary of Gilead Sciences, has made public plans to push back by roughly one year the planned achievement of commercial production at its site in Urbana. Alert readers will recall that the company is constructing a new 279,000-square-foot plant in Urbana, Maryland after purchasing the 20 acre property on Bennett Creek Blvd in November 2018 for $7.5 million. The project delay is being attributed to building enhancements. It is understood that the new site will manufacture Kite's producers of chimeric antigen receptor T (CAR T) therapies, including Yescarta, which is Kite Pharma's commercially available CAR T therapy. Learn More

Janssen has announced a significant investment to expand its R&D presence and capabilities in the San Francisco Bay Area. This investment will support the leasing and construction of a state-of-the-art R&D facility in the global innovation center of South San Francisco, CA. Janssen executed the lease at The Shore at Sierra Point in Brisbane, CA. Janssen personnel at this new facility will focus on infectious and retinal diseases, data science and emerging modalities within discovery, product development and supply. The expanded facility is projected to more than double Janssen's presence in South San Francisco and is anticipated to be fully operational in 2022, upon completion of construction. Learn More

G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, this week unveiled another facility expansion, adding to the company's 200,000 sq. ft. manufacturing site in College Station, TX. The new facility, opening January 2020, consists of 25,000 sq. ft. of manufacturing space dedicated to POD architectural, mechanical, electrical and automation fit out. This development completes Phase 4 of G-CON's growth at its manufacturing site in Texas. G-CON recently announced another 25,000 sq. ft. facility expansion for superstructures, doubling the company's superstructure capacity. Learn More

Rooster Bio has made public plans to expand its site in Frederick, Maryland by roughly 30%, adding an additional 5,000 sq. ft. to its existing 15,500 sq. ft. footprint. This is the second expansion of the site since 2019. The biopharma is focused on developing and manufacturing human adult stem cells and stem cell-based products, supplying human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems. The driver behind this expansion is increasing global demand for the company's products and services. According to published reports, this expansion will include additional jobs. Learn More

Bristol-Myers Squibb announced this week that it has completed its previously announced divestment of its 208,000 sq. ft. oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent. The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. The divestiture is part of Bristol-Myers Squibb's strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline. Learn More

Joinn Biologics has secured $60 million in Series A financing to help it build a comprehensive biopharma service platform designed to enable the company to achieve recognition as a leading CDMO for biologics globally. To that end, the company had made public plans to construct a biologics manufacturing facility equipped with 100,000-liters of capacity in China. Additionally, the company is understood to be planning expansion at its operations in the U.S. Alert readers will recall that Joinn, founded in 2018, currently has 2,000 liters of capacity in Richmond, California and 1,400 liters of capacity currently in place in China. Learn More

AGC Biologics is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. The expansion of the site includes a pDNA manufacturing process improvement project that enables the extension of the offer in hosts and plasmids (low and high copy pDNA expression systems) via a large toolbox in process development with scales of 1L to 10L for High Quality pDNA. These processes can easily be scaled up to fit into the established 50L, 100L, 500L or 1000L GMP manufacturing. This expanded site joins AGC microbial facilities in Heidelberg (Germany), Copenhagen (Denmark) and Chiba (Japan), and soon an additional microbial facility in Seattle (United States). Learn More

Symbiosis Pharmaceutical Services has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.  The company has invested more than $1.9 million in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq.-ft. of space to house administrative, management and operational teams, as well as the expansion of its manufacturing space and its supporting services infrastructure. The new operational area also provides additional capacity for GMP-compliant manufacturing services for supply chain management, additional temperature-controlled storage, and the company's first automated labelling and packaging equipment. Learn More

Wuxi Biologics have been given the go ahead for phase two of their site at the IDA Ireland Dundalk Science and Technology Park at Mullagharlin. This will include construction of a new three-story, 167,000 sq. ft. vaccine production facility. Additionally, a 95,000 sq. ft., four-story lab and administration building will also be built as will a two-story, 9,000 sq. ft., modular support lab. Alert readers will recall that last month Wuxi announced plans to build a $240 million vaccine production facility on the new campus. This comes amid reports that Wuxi intends to also invest heavily in microbial fermentation capacity at its site in China. Learn More

The largest biotechnology incubator of its kind in New York City, BioLabs@NYULangone, opened this week at 180 Varick Street in Manhattan. The 50,000 sq. ft. of newly renovated and fully equipped laboratory and office space will eventually be home to more than 35 early -stage biotechnology and life science companies. Currently, 22 biotech companies reside in the space. Companies selected for BioLabs@NYULangone will start with a package of tailored laboratory equipment and supplies. BioLabs staff will provide educational programming and operational support, enabling startups to focus on science and innovation, and ultimately move more quickly into their own spaces. Learn More

CatSci, a contract research organization (CRO), is furthering its expansion strategy to deliver tailored chemistry services to support the Chemistry, Manufacturing and Controls (CMC) demands of its global biopharma customers. The expansion includes the addition of two new laboratories. These are new facilities that have been refurbished to enable CatSci to scale out its best-in-class process research and development operations for API synthesis and manufacturing. This is in addition to laboratories that have been launched this year, which include a scale-up facility, 20L vessels for material supply and analytical facilities for non-GMP analytical development. Learn More

Merck will invest $57 million to expand vaccine manufacturing capabilities at its site in Wilson, North Carolina for production of RotaTeq which protects babies from rotavirus. "Merck is delighted to announce its second significant investment at our Wilson plant in less than a year," said Sanat Chattopadhyay, Executive Vice President and President, Merck Manufacturing Division. This latest commitment will enable us to introduce a new and innovative filling and packaging technology to assist in the production of our important RotaTeq vaccine. We appreciate all the support we've received for this project from Governor Cooper, Secretary Copeland and his staff, and from Wilson County." Learn More

BioMed Realty has inked a 240,000-square-foot lease with Amgen at its Gateway of Pacific campus in South San Francisco. The new long-term deal at the 1.3-million-square-foot life science campus that is currently under construction will house Amgen's Bay Area scientists and employees focused on cardiometabolic, inflammation and oncology research. BioMed also recently signed leases with leading innovation companies, including Zymergen for 304,000 square feet to relocate its headquarters to BioMed's Emeryville Center of Innovation in the Bay Area. Learn More

Thermo Fisher Scientific has opened a $90 million, 50,000-square-foot viral vector manufacturing facility in Lexington, Massachusetts. The contract development and manufacturing organization expects to create more than 200 jobs at the site, which will support development, testing and manufacturing for viral vectors, the inactivated viruses used to deliver gene therapies. According to the company the new site will help address a "bottleneck" in manufacturing viral vectors. Alert readers will recall that Thermo Fisher paid $1.7 billion earlier this year for viral vector contract manufacturer Brammer Bio. Learn More

Eli Lilly and Company this week unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise. With over 65,000 square feet of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and workstations. Learn More

Singapore has announced that its research and development hub Biopolis will be expanded to meet the needs of biotechnology start-ups. Phase 6 of Biopolis will add a further 376,000+ sq. ft. (35,000 sq m) of business park space for biomedical sciences research and supporting activities and 64,000+ sq. ft. (6,000 sq m) for office and retail use. This will include 21,000+ sq. ft. (2,000 sq m) of fitted-out laboratory spaces with lab benches, waste drainage and exhaust provisions. Biopolis currently houses nine A*Star research institutes and over 60 companies, with thousands of employees undertaking research, clinical trials and commercialization of new scientific discoveries. Learn More

Novartis has opened a new manufacturing facility for cell and gene therapies in Switzerland. In addition to manufacturing areas for novel CAR-T cell therapies, the new building also hosts the production of innovative, difficult-to-manufacture solid dosage forms such as tablets and capsules. In September 2019, the first clinical production of a cell and gene therapy batch was successfully completed. The $90 million facility is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020. The Swiss facility, as well as a separate French site also being expanded, are central to Novartis's plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises. Learn More

Plans are moving forward for another Bay Area biotech campus. Alexandria Real Estate Equities is transforming a chunk of property in San Carlos, California into a 1.6 million-square-foot biotech campus. According to the San Francisco Business Times, the real estate development company submitted plans for its proposed biotech campus. Alexandria Real Estate Equities intends to turn the space into six new buildings, each about five to seven floors for biotech companies to use. In addition to the buildings, the site will also include an amenities structure, parking garages and a small park, according to the Business Times. Learn More

Horizon Therapeutics has announced the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions. Horizon plans to add new positions in bioanalysis, clinical research, pharmacology, manufacturing and business development during the next year. Learn More

Maravai LifeSciences has unveiled its new $40 million headquarters this week in San Diego, California. In addition to doubling overall manufacturing capacity by adding a 50,000 sq. ft. manufacturing facility, TriLink BioTechnologies, a Maravai LifeSciences company  whose headquarters will also be housed in the new facility, has added five new Current Good Manufacturing Practice (cGMP) suites, for a total of six, that can be specifically tailored for customer drug development campaigns including scaleup for Phase I clinical trials. The new 105,000-square-foot facility houses the company's current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. Learn More

Eli Lilly and Co. will invest $400 million in its manufacturing facility in Indianapolis, an upgrade that will lead to an additional 100 highly skilled jobs at the Indianapolis-based drug manufacturer. The money will go to enhancing the existing facilities at the Lilly Technology Center campus, which manufactures insulin. It will also help Lilly increase its capacity to make other diabetes medicine, company officials said in a news release. In addition to insulin, Lilly makes 10 non-insulin diabetes drugs. Company officials said that the money announced this week would go to improving the company's syringe-filling, device assembly and packaging operations. Learn More

Arkuda Therapeutics, a biotechnology company developing therapies to change the trajectory of neurodegenerative disease, has signed a 10,819 square foot lease at Arsenal Yards' new state-of-the-art life science lab space. The biotech becomes the latest in a growing number of emerging biopharma companies to relocate from Kendall Square in Cambridge to Watertown's biotech cluster. Arsenal Yards boasts more than one million square feet of development including lab and office space. Learn More

Fujifilm Diosynth Biotechnologies has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development laboratories. As part of a capital investment of approximately $120 million in the gene therapy field by FUJIFILM Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacent to the existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas. The Gene Therapy Innovation Center will be approximately 60,000 square feet and house state-of-the-art upstream, downstream and analytical development technologies. The facility will be operational in the fall of 2021. Learn More

CMO CMIC has leased 233,000 sq. ft. at 270 Prospect Plains Rd. in Cranbury, NJ. The site will be used for office, research and development, production, packaging, manufacturing, warehousing and distribution. The deal involved negotiating a lease termination with an existing tenant, Sun Pharmaceutical, and arranging for the purchase of in-place research and development infrastructure. Learn More

Rentschler Biopharma is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a 500L single-use bioreactor for the 93,000 square foot facility near Boston, MA. The XDR-500 bioreactor, with a working volume of 100-500 L, is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Learn More

Takeda this week opened a new plant in Singen, Germany that will manufacture the company's experimental dengue vaccine, which is newly supported by Phase 3 results that appear to show the shot is effective in guarding against the mosquito-borne viral disease. The biopharma has invested more than $140 million over the past three years as it built the facility, which will employ as many as 200 people once operational. Takeda first began construction in 2016, and the plant is now ready for packaging production. End-to-end production of the vaccine, known as TAK-003, will be ready nearer to when Takeda expects to secure licensure of the drug. Learn More

AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The biopharma giant has also set up a $1 billion fund to foster biotech innovation in that country. The move will see the AstraZeneca found a global R&D center in Shanghai's central Jing'an district. The company currently operates R&D centers at its Cambridge, UK, headquarters as well as at sites in Maryland and Sweden. The new China facility will carry out R&D for innovative drugs, with the focus being on diseases that are prevalent in China. The site will bring AstraZeneca's R&D headcount in China to 1,000 people. The industry leaders says it has no plans to co-locate all China R&D facilities. Learn More

Azurity Pharma, formed in May has picked 8 Cabot Road in Woburn for its new expanded corporate headquarters. The company will relocate from Presidential Way to 14,627 square feet within the 60,000-square-foot 8 Cabot Road office building. Azurity specializes in drug delivery systems including ones optimized for children and the elderly. The company was formed in May when CutisPharma acquired Silvergate Pharmaceuticals and rebranded the combined company. Along with the Woburn headquarters, Azurity has a manufacturing facility in Wilmington. Learn More

San Diego will create California's first "capacity bank" for water and sewer, allowing breweries and biotech firms to cheaply buy excess water and sewer capacity from former factories. The City Council unanimously approved the capacity bank, calling it an innovative idea that will create jobs and help the city avoid expensive expansions of its sewer and water infrastructure. The council also unanimously approved a companion proposal that geographically expands and softens the qualifications for the city's "guaranteed water" program, which ensures local firms access to water during droughts or other kinds of shortages. Learn More

Prelude Therapeutics, one of the biotech companies growing up in the state-backed Delaware Innovation Space at the DuPont Experimental Station just outside Wilmington, has pledged to hire up to 49 biotech professionals and find larger quarters in the state, to win a commitment for taxpayer financing. Founded in 2016, Prelude plans to invest $5 million in its new headquarters, state officials said in a statement. The state-funded Council on Development Finance has agreed to give Prelude $830,000 in Delaware Strategic Fund grants, based on the company's meeting its hiring goals to boost its current 32 workers to 81 over the next three years, including scientists and "skilled associates." Learn More

Teesside University in the United Kingdom has officially opened its $28 million National Horizons Centre, which it believes will catalyze talent development and increase engagement between research, teaching and industry. The university already has collaborative partnerships with companies such as Fujifilm Diosynth Biotechnologies and GlaxoSmithKline, which officials say will ensure a foundation for the development of industry-relevant training and work-ready graduates. Among the new equipment featured at the state of the art center are glass and steel bioreactors and bioreactor controllers from Applikon. Learn More

WuXi Biologics plans to build a four-storey vaccine manufacturing plant which will bring a further 200 jobs to Dundalk, Ireland. WuXi has already commenced building a $360 million factory on their Mullagharlin Road site in Dundalk. A new company called WuXi Vaccines Ireland submitted the plans for an additional 167,000 sq. ft. of new buildings to Louth County Council, to be built to the north of the site adjacent to the Mullaharlin Road, earlier this month. The newly-proposed facility will comprise of one main integrated administration, manufacturing and warehouse building with some ancillary buildings. Learn More

Anpac Bio has signed a 10-year lease on a newly constructed 6,724-square-foot office at the Spring House Innovation Park in Pennsylvania. The company, founded in 2008, had been looking to expand to the East Coast. Anpac, which will keep its office in San Jose, will bring 10 of its 100 employees to the Spring House complex in the spring. Alert readers mights recognize the name of the industrial park, it is home to a number of other biopharma industry suppliers and end users including Chromatan. Learn More